David T Gilbertson1, Brian D Bradbury2, James B Wetmore1, Eric D Weinhandl1, Keri L Monda2, Jiannong Liu1, M Alan Brookhart3, Sally K Gustafson1, Tricia Roberts1, Allan J Collins1,4, Kenneth J Rothman5,6. 1. Chronic Disease Research Group, Minneapolis Medical Research Foundation, Minneapolis, MN, USA. 2. Center for Observational Research, Amgen, Inc., Thousand Oaks, CA, USA. 3. Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. 4. Department of Medicine, University of Minnesota, Minneapolis, MN, USA. 5. RTI Health Solutions, Research Triangle Park, NC, USA. 6. Department of Epidemiology and Medicine, Boston University Medical Center, Boston, MA, USA.
Abstract
PURPOSE: Confounding, a concern in nonexperimental research using administrative claims, is nearly ubiquitous in claims-based pharmacoepidemiology studies. A fixed-length look-back window for assessing comorbidity from claims is common, but it may be advantageous to use all historical claims. We assessed how the strength of association between a baseline-identified condition and subsequent mortality varied by when the condition was measured and investigated methods to control for confounding. METHODS: For Medicare beneficiaries undergoing maintenance hemodialysis on 1 January 2008 (n = 222 343), we searched all Medicare claims, 1 January 2001 to 31 December 2007, for four conditions representing chronic and acute diseases, and classified claims by number of months preceding the index date. We used proportional hazard models to estimate the association between time of condition and subsequent mortality. We simulated a confounded comorbidity-exposure relationship and investigated an alternative method of adjustment when the association between the condition and mortality varied by proximity to follow-up start. RESULTS: The magnitude of the mortality hazard ratio estimates for each condition investigated decreased toward unity as time increased between index date and most recent manifestation of the condition. Simulation showed more biased estimates of exposure-outcome associations if proximity to follow-up start was not considered. CONCLUSIONS: Using all-available claims information during a baseline period, we found that for all conditions investigated, the association between a comorbid condition and subsequent mortality varied considerably depending on when the condition was measured. Improved confounding control may be achieved by considering the timing of claims relative to follow-up start.
PURPOSE: Confounding, a concern in nonexperimental research using administrative claims, is nearly ubiquitous in claims-based pharmacoepidemiology studies. A fixed-length look-back window for assessing comorbidity from claims is common, but it may be advantageous to use all historical claims. We assessed how the strength of association between a baseline-identified condition and subsequent mortality varied by when the condition was measured and investigated methods to control for confounding. METHODS: For Medicare beneficiaries undergoing maintenance hemodialysis on 1 January 2008 (n = 222 343), we searched all Medicare claims, 1 January 2001 to 31 December 2007, for four conditions representing chronic and acute diseases, and classified claims by number of months preceding the index date. We used proportional hazard models to estimate the association between time of condition and subsequent mortality. We simulated a confounded comorbidity-exposure relationship and investigated an alternative method of adjustment when the association between the condition and mortality varied by proximity to follow-up start. RESULTS: The magnitude of the mortality hazard ratio estimates for each condition investigated decreased toward unity as time increased between index date and most recent manifestation of the condition. Simulation showed more biased estimates of exposure-outcome associations if proximity to follow-up start was not considered. CONCLUSIONS: Using all-available claims information during a baseline period, we found that for all conditions investigated, the association between a comorbid condition and subsequent mortality varied considerably depending on when the condition was measured. Improved confounding control may be achieved by considering the timing of claims relative to follow-up start.
Authors: Glenn M Chertow; Jiannong Liu; Keri L Monda; David T Gilbertson; M Alan Brookhart; Anne C Beaubrun; Wolfgang C Winkelmayer; Allan Pollock; Charles A Herzog; Akhtar Ashfaq; Til Sturmer; Kenneth J Rothman; Brian D Bradbury; Allan J Collins Journal: J Am Soc Nephrol Date: 2016-02-25 Impact factor: 10.121
Authors: Magdalene M Assimon; M Alan Brookhart; Jason P Fine; Gerardo Heiss; J Bradley Layton; Jennifer E Flythe Journal: Am J Kidney Dis Date: 2018-04-10 Impact factor: 8.860
Authors: Paige D Wartko; Noel S Weiss; Daniel A Enquobahrie; K C Gary Chan; Alyssa Stephenson-Famy; Beth A Mueller; Sascha Dublin Journal: Pharmacoepidemiol Drug Saf Date: 2019-07-12 Impact factor: 2.890
Authors: Paige D Wartko; Noel S Weiss; Daniel A Enquobahrie; Kwun Chuen Gary Chan; Alyssa Stephenson-Famy; Beth A Mueller; Sascha Dublin Journal: Am J Perinatol Date: 2020-06-30 Impact factor: 1.862
Authors: Paige D Wartko; Noel S Weiss; Daniel A Enquobahrie; K C Gary Chan; Alyssa Stephenson-Famy; Beth A Mueller; Sascha Dublin Journal: J Clin Psychopharmacol Date: 2021 Jul-Aug 01 Impact factor: 3.153
Authors: David Cheng; Clark DuMontier; Cenk Yildirim; Brian Charest; Chelsea E Hawley; Min Zhuo; Julie M Paik; Enzo Yaksic; J Michael Gaziano; Nhan Do; Mary Brophy; Kelly Cho; Dae H Kim; Jane A Driver; Nathanael R Fillmore; Ariela R Orkaby Journal: J Gerontol A Biol Sci Med Sci Date: 2021-06-14 Impact factor: 6.053